MA31843B1 - Utilisation d'un bêta-bloquant pour la fabrication d'un médicament pour le traitement des hémangiomes - Google Patents

Utilisation d'un bêta-bloquant pour la fabrication d'un médicament pour le traitement des hémangiomes

Info

Publication number
MA31843B1
MA31843B1 MA32829A MA32829A MA31843B1 MA 31843 B1 MA31843 B1 MA 31843B1 MA 32829 A MA32829 A MA 32829A MA 32829 A MA32829 A MA 32829A MA 31843 B1 MA31843 B1 MA 31843B1
Authority
MA
Morocco
Prior art keywords
blocker
beta
hemangiomas
treatment
medicament
Prior art date
Application number
MA32829A
Other languages
Arabic (ar)
English (en)
Inventor
Christine Léauté-Labrèze
De La Roque Éric Dumas
Alain Taieb
Jean-Benoît Thambo
Original Assignee
Université Victor Segalen Bordeaux 2
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31843(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université Victor Segalen Bordeaux 2 filed Critical Université Victor Segalen Bordeaux 2
Publication of MA31843B1 publication Critical patent/MA31843B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La présente invention concerne l'utilisation d'un bêta-bloquant pour la fabrication d'un médicament pour le traitement des hémangiomes, par exemple des hémangiomes infantiles. Le bêta-bloquant peut être un bêta-bloquant non sélectif, par exemple le propranolol. La présente invention fournit une alternative aux composés connus, p. Ex. Aux cordicostéroïdes, à l'interféron ou à la vincristine, généralement utilisés pour le traitement des hémangiomes.
MA32829A 2007-10-19 2010-05-10 Utilisation d'un bêta-bloquant pour la fabrication d'un médicament pour le traitement des hémangiomes MA31843B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291273A EP2050441A1 (fr) 2007-10-19 2007-10-19 Utilisation de bêtabloquants pour la fabrication d'un médicament pour le traitement d'hémangiomes
US98950707P 2007-11-21 2007-11-21
PCT/IB2008/002746 WO2009050567A2 (fr) 2007-10-19 2008-10-16 Utilisation d'un bêta-bloquant pour la fabrication d'un médicament pour le traitement des hémangiomes

Publications (1)

Publication Number Publication Date
MA31843B1 true MA31843B1 (fr) 2010-11-01

Family

ID=39156667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32829A MA31843B1 (fr) 2007-10-19 2010-05-10 Utilisation d'un bêta-bloquant pour la fabrication d'un médicament pour le traitement des hémangiomes

Country Status (31)

Country Link
US (2) US8338489B2 (fr)
EP (3) EP2050441A1 (fr)
JP (1) JP5552700B2 (fr)
KR (2) KR20150110827A (fr)
CN (2) CN102006864B (fr)
AR (1) AR068927A1 (fr)
AT (1) ATE512661T1 (fr)
AU (1) AU2008313405B2 (fr)
BR (1) BRPI0816536A2 (fr)
CA (1) CA2701953C (fr)
CL (1) CL2008003083A1 (fr)
CO (1) CO6270209A2 (fr)
CY (1) CY1112604T1 (fr)
DE (1) DE08838691T1 (fr)
DK (2) DK2233135T3 (fr)
ES (2) ES2390534T3 (fr)
HK (1) HK1148940A1 (fr)
HR (2) HRP20110659T1 (fr)
IL (1) IL205129A (fr)
MA (1) MA31843B1 (fr)
MX (1) MX2010004295A (fr)
MY (1) MY156750A (fr)
NZ (1) NZ584307A (fr)
PA (1) PA8799401A1 (fr)
PL (2) PL2233135T3 (fr)
PT (2) PT2187878E (fr)
RU (1) RU2471500C2 (fr)
SI (2) SI2233135T1 (fr)
TN (1) TN2010000170A1 (fr)
TW (1) TWI531365B (fr)
WO (1) WO2009050567A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050441A1 (fr) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Utilisation de bêtabloquants pour la fabrication d'un médicament pour le traitement d'hémangiomes
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
WO2010118340A1 (fr) 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Traitement d'un hémangiome cutané
EP2246044A1 (fr) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Solutions pédiatriques de bêta-bloquants
US20140170112A1 (en) * 2011-03-12 2014-06-19 Vicus Therapeutics, Llc Compositions for ameliorating systemic inflammation and methods for making and using them
CN102579412A (zh) * 2012-02-16 2012-07-18 山东省立医院 一种治疗婴幼儿血管瘤的外用药物及其制备方法
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
CN103054793B (zh) * 2013-01-05 2015-01-21 广州军区广州总医院 一种用于治疗婴幼儿血管瘤的盐酸普萘洛尔乳膏及其制备方法
WO2014150899A1 (fr) * 2013-03-15 2014-09-25 Chapin Matthew J Formulations ophtalmiques topiques pour traiter la migraine
CN104274390B (zh) * 2014-09-04 2017-06-13 郑家伟 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用
RU2584082C1 (ru) * 2015-01-21 2016-05-20 Ильдар Наилевич Нурмеев Способ лечения гемангиом
CN105434337B (zh) * 2015-04-03 2019-08-16 武汉科福新药有限责任公司 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途
CN105106105A (zh) * 2015-08-14 2015-12-02 天津市聚星康华医药科技有限公司 噻吗洛尔外用制剂治疗婴幼儿血管瘤的应用及其制备方法
US20170360829A1 (en) * 2016-01-27 2017-12-21 Gillies Mcindoe Research Institute Treatment of vascular anomalies
RU2617516C1 (ru) * 2016-03-24 2017-04-25 Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт неотложной детской хирургии и травматологии Департамента здравоохранения города Москвы Способ лечения младенческих гемангиом
CN106474061B (zh) * 2016-12-08 2019-01-22 黑龙江童医生儿童生物制药有限公司 一种盐酸普萘洛尔口服乳剂及其制备方法
CN108261411B (zh) * 2016-12-30 2021-04-30 武汉科福新药有限责任公司 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法
US11730707B2 (en) 2017-08-07 2023-08-22 Alianza Española De Familias De Von Hippel-Lindau-Vhl Compounds for treating von Hippel-Lindau disease
US20190133974A1 (en) 2017-11-07 2019-05-09 University Of South Florida Methods for detecting and treating propranolol sensitive tumors
CN108299279B (zh) * 2018-02-09 2021-03-23 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
CN110314154A (zh) * 2018-03-28 2019-10-11 武汉恒信源药业有限公司 左旋普萘洛尔在制备治疗血管病变药物中的应用
US20210346319A1 (en) * 2018-10-04 2021-11-11 Emory University Pharmaceutical Compositions of R-(+)-Propranolol in Enantiomeric Excess and Therapeutic Uses Related Thereto
RU2701213C1 (ru) * 2018-12-27 2019-09-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Способ лечения инфантильных гемангиом
US11154518B2 (en) * 2018-12-28 2021-10-26 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound
CA3139865A1 (fr) * 2019-05-24 2020-12-03 Pediatric Derm Developement Llc Traitement de l'hemangiome infantile
CN111773226A (zh) * 2019-06-26 2020-10-16 首都医科大学附属北京儿童医院 噻吗洛尔或其盐在制备预防和/或治疗丛状血管瘤的药物中的用途
MA57759A1 (fr) * 2020-01-29 2023-04-28 Gillies Mcindoe Res Institute Méthodes et compositions pour le traitement de l'hémangiome
WO2022007878A1 (fr) * 2020-07-10 2022-01-13 长庚医疗财团法人林口长庚纪念医院 UTILISATION D'UN ANTAGONISTE DE L'ADRÉNORÉCEPTEUR β-1 POUR LA PRÉPARATION D'UNE COMPOSITION DE RÉDUCTION DES LÉSIONS DES CELLULES ÉPITHÉLIALES INDUITES PAR L'INHIBITEUR DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE ET D'INHIBITION DES CELLULES CANCÉREUSES
US20230364242A1 (en) 2020-09-30 2023-11-16 Nissan Chemical Corporation Water-soluble complex containing beta blocker and lecithin
CN113274348A (zh) * 2021-06-11 2021-08-20 四川大学华西医院 用于治疗婴幼儿血管瘤的阿替洛尔凝胶、制备方法及应用
PL244294B1 (pl) * 2022-09-20 2024-01-03 Univ Medyczny W Lodzi Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL301580A (fr) * 1962-12-11
US3466325A (en) * 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
GB1253709A (en) 1968-05-22 1971-11-17 Frosst & Co Charles E Thiadiazole derivatives
US3657237A (en) * 1968-05-22 1972-04-18 Frosst & Co Charles E Process for making 1 2 5-thiadiazoles in the sinister configuration
US3655663A (en) * 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
SE354851B (fr) 1970-02-18 1973-03-26 Haessle Ab
AT334385B (de) * 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
FR2330383A1 (fr) * 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US5116867A (en) * 1989-06-30 1992-05-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services D-propranolol as a selective adenosine antagonist
US5182102A (en) * 1991-07-12 1993-01-26 Alcon Laboratories, Inc. Anti-glaucoma compositions
DE69435342D1 (de) * 1993-07-19 2011-05-05 Angiotech Pharm Inc Anti-Angiogene Mittel und Verfahren zu deren Verwendung
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
WO1997040830A1 (fr) * 1996-05-01 1997-11-06 Eli Lilly And Company Traitement therapeutique des maladies liees au facteur de croissance de l'endothelium vasculaire
GB9616672D0 (en) * 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
US7459470B2 (en) * 2001-05-08 2008-12-02 Schering Ag N-oxide anthranylamide derivatives and their use as medicaments
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
CA2576255A1 (fr) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Utilisation d'agonistes et d'antagonistes de beta-adrenocepteurs pour traiter les maladies arterielles
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
EP2050441A1 (fr) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Utilisation de bêtabloquants pour la fabrication d'un médicament pour le traitement d'hémangiomes
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Also Published As

Publication number Publication date
EP2187878A2 (fr) 2010-05-26
CN103169971A (zh) 2013-06-26
CN102006864A (zh) 2011-04-06
RU2010112816A (ru) 2011-11-27
EP2233135A1 (fr) 2010-09-29
US20100273889A1 (en) 2010-10-28
KR20150110827A (ko) 2015-10-02
KR101562627B1 (ko) 2015-10-22
PT2187878E (pt) 2011-09-07
TWI531365B (zh) 2016-05-01
EP2050441A1 (fr) 2009-04-22
PL2187878T3 (pl) 2012-01-31
CO6270209A2 (es) 2011-04-20
DE08838691T1 (de) 2010-08-26
MX2010004295A (es) 2010-08-02
DK2187878T3 (da) 2011-09-19
CL2008003083A1 (es) 2009-03-06
ES2390534T3 (es) 2012-11-13
AU2008313405A1 (en) 2009-04-23
ES2368299T3 (es) 2011-11-16
HRP20110659T1 (hr) 2011-10-31
HRP20120765T1 (hr) 2012-10-31
RU2471500C2 (ru) 2013-01-10
PA8799401A1 (es) 2009-05-15
PL2233135T3 (pl) 2012-11-30
CN102006864B (zh) 2013-01-16
KR20100087012A (ko) 2010-08-02
IL205129A (en) 2015-05-31
AR068927A1 (es) 2009-12-16
US9173858B2 (en) 2015-11-03
DK2233135T3 (da) 2012-10-01
JP5552700B2 (ja) 2014-07-16
JP2011500661A (ja) 2011-01-06
ATE512661T1 (de) 2011-07-15
WO2009050567A3 (fr) 2009-06-18
CA2701953C (fr) 2015-05-19
CY1112604T1 (el) 2016-02-10
HK1148940A1 (en) 2011-09-23
US8338489B2 (en) 2012-12-25
SI2233135T1 (sl) 2012-10-30
SI2187878T1 (sl) 2011-10-28
EP2233135B1 (fr) 2012-06-27
BRPI0816536A2 (pt) 2017-06-06
TW200932207A (en) 2009-08-01
IL205129A0 (en) 2010-11-30
AU2008313405B2 (en) 2013-12-19
EP2233135B8 (fr) 2013-07-10
WO2009050567A2 (fr) 2009-04-23
PT2233135E (pt) 2012-09-06
NZ584307A (en) 2012-03-30
TN2010000170A1 (en) 2011-11-11
EP2187878B1 (fr) 2011-06-15
MY156750A (en) 2016-03-31
CA2701953A1 (fr) 2009-04-23
US20130072551A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
MA31843B1 (fr) Utilisation d'un bêta-bloquant pour la fabrication d'un médicament pour le traitement des hémangiomes
MA42795B1 (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
MA31907B1 (fr) Nouveaux herbicides
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
ID29552A (id) Senyawa-senyawa triazola dan penggunaannya
IN2014DN08578A (fr)
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA31918B1 (fr) Agents et épitopes de liaison à wise
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA31884B1 (fr) Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
TNSN06300A1 (fr) Derives d'imidazole pour le traitement de troubles neurodegeneratifs
MA32506B1 (fr) Nouveaux composes
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
GEP20084499B (en) USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
MA54386B1 (fr) Modulateurs de trex1
MA27549A1 (fr) N-sulfonyl-4-methylene-amino-3-hydroxy-2-pyridones
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
MA31699B1 (fr) Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3